BALCAO · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · SMALL CAP
Cyanotech Corp. CYAN
16 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
$24.2M
▲ 5.0% vs FY2023
EPS · FY24
—
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
-30.9%
Net margin · FY24
-13.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 24.2M
Revenue, FY2024 · full 16-year series below
Revenue
Net income
The company lost 13 cents on every revenue dollar this year.
Per share
—
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
-30.9%
Return on equity, FY2024
ROE
Operating margin-10.4%
Net margin-13.2%
Return on assets-13.2%
Each USD of equity lost 31 cents this year.
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−5.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−12.4%
−5.4%
−3.3%
+2.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2024
Change, 5 years+19.8%
Change, 10 years+29.4%
The share count grew 20% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 23.5M
total assets, end of FY2024
Total assetsUSD 23.5M
EquityUSD 8.9M
CashUSD 257,000.00
Gross debtUSD 3.9M
Net debtUSD 3.6M
Current ratio1.03×
Net debt stands at 41% of equity.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
−0.0
−0.0
0.0
−0.0
0.0
0.0
0.0
0.0
EBITDA $B
−0.0
−0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
0.0
Net income $B
−0.0
−0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
EPS, diluted $
·
−0.81
−0.55
0.35
0.15
0.06
−0.62
0.18
−0.21
−0.79
0.00
−0.08
0.74
0.66
0.32
0.26
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−30.9
−37.4
−19.2
11.8
5.6
2.5
−21.8
5.9
−7.1
−22.4
−0.1
−2.1
23.5
27.6
17.1
15.3
Shares out B
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
61 of 61
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed